News
AACI Endorses 340B PATIENTS Act
AACI has endorsed HR 7635, the Pharmaceutical Access to Invest in Essential, Needed Treatments & Support Act (340B PATIENTS Act). Introduced in March 2024 by Representative Doris Matsui (D-CA), the legislation aims to protect and strengthen the 340B program via codification of the ability to use contract pharmacies to dispense 340B discounted drugs. This would ensure that 340B patients are able to get their prescriptions at any local pharmacy and ensure that safety-net providers can continue to provide medical and social services in their community with 340B discount savings.
Specifically, the 340B PATIENTS Act would:
- Clarify that manufacturers are required to offer 340B discount prices to covered entities regardless of the manner or location in which a drug is dispensed, including if a covered entity uses a contract pharmacy to dispense 340B drugs to the entity’s patients
- Ensure that manufacturers cannot place conditions on the ability of a covered entity to purchase and use 340B drugs, regardless of the manner or location in which the drug is dispensed, including through contract pharmacies
- Impose civil monetary penalties on manufacturers that violate these statutory requirements and prohibitions
AACI encourages members to sign on to a support letter for the legislation. If you are interested in signing on, please email [email protected] to indicate your support.